BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BioMarin Pharmaceutical Inc.

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Royalty and Other Revenue

Royalty and Other Revenue % Chg.

Royalty and Other Revenue Common Size

United States Revenue

United States Revenue % Chg.

United States Revenue Common Size

Europe Revenue

Europe Revenue % Chg.

Europe Revenue Common Size

Latin America Revenue

Latin America Revenue % Chg.

Latin America Revenue Common Size

Rest of World Revenue (Pre-Q3 2024)

Rest of World Revenue (Pre-Q3 2024) % Chg.

Rest of World Revenue (Pre-Q3 2024) Common Size

Rest of World Revenue (Post-Q2 2024)

Rest of World Revenue (Post-Q2 2024) % Chg.

Rest of World Revenue (Post-Q2 2024) Common Size

Other Revenue by Geography

Other Revenue by Geography % Chg.

Other Revenue by Geography Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

VOXZOGO Revenue

VOXZOGO Revenue % Chg.

VOXZOGO Revenue Common Size

VIMIZIM Revenue

VIMIZIM Revenue % Chg.

VIMIZIM Revenue Common Size

NAGLAZYME Revenue

NAGLAZYME Revenue % Chg.

NAGLAZYME Revenue Common Size

PALYNZIQ Revenue

PALYNZIQ Revenue % Chg.

PALYNZIQ Revenue Common Size

ALDURAZYME Revenue

ALDURAZYME Revenue % Chg.

ALDURAZYME Revenue Common Size

BRINEURA Revenue

BRINEURA Revenue % Chg.

BRINEURA Revenue Common Size

KUVAN Revenue

KUVAN Revenue % Chg.

KUVAN Revenue Common Size

ROCTAVIAN Revenue

ROCTAVIAN Revenue % Chg.

ROCTAVIAN Revenue Common Size

FIRDAPSE Revenue

FIRDAPSE Revenue % Chg.

FIRDAPSE Revenue Common Size

Total Net Product Revenue

Total Net Product Revenue % Chg.

Total Net Product Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Middle East Revenue

Middle East Revenue % Chg.

Middle East Revenue Common Size

Revenue	LTM	Dec '24	Dec '23
VOXZOGO Revenue	862	735.1	469.9
VIMIZIM Revenue	777.6	739.8	701.1
NAGLAZYME Revenue	475.2	479.6	420.3
PALYNZIQ Revenue	408.4	355	303.9
ALDURAZYME Revenue	198.2	183.9	131.2
BRINEURA Revenue	184.7	169.1	161.9
KUVAN Revenue	104.5	120.9	180.8
ROCTAVIAN Revenue	33.4	26.1	3.5
FIRDAPSE Revenue	—	—	—
Total Net Product Revenue	3,044.1	2,809.4	2,372.5
Royalty and Other Revenue	49.9	44.5	46.7
Total Revenue	3,094	2,853.9	2,419.2

Revenue by Geography	LTM	Dec '24	Dec '23
Royalty and Other Revenue	49.9	44.5	46.7
United States Revenue	1,057.2	924.8	771.3
Europe Revenue	889.2	829	669.3
Latin America Revenue	387.2	378.1	332.4
Rest of World Revenue (Pre-Q3 2024)	—	—	468.2
Rest of World Revenue (Post-Q2 2024)	512.3	493.6	468.2
Other Revenue by Geography	198.2	183.9	131.2
Total Revenue by Geography	3,094	2,853.9	2,419.2